These findings suggest a viable therapeutic strategy in managing MDSC invasion through the CCL2/CCR2 pathway, offering an enhanced immunotherapy approach for pancreatic cancer patients. The gene discussed is CCL2; the disease is familial pancreatic carcinoma.